Phase 1/2RecruitingAge-related condition
Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.
A Phase 1/2a Multi-Center, Dose-Escalation Study to Evaluate the Safety & Efficacy of Eyecyte-RPE™ When Administered as a Single-dose Subretinal Injection in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- Sponsor
- Eyestem Research Pvt. Ltd. (Industry)
- Enrolment
- 54 planned
- Conditions
- Retinal Disease; Macular Degeneration; Age-Related Macular Degeneration; Geographic Atrophy; Eye Diseases
- Interventions
- Eyecyte-RPE™
- Ages
- adults, older adults
- Registry
- NCT06394232
Full record on ClinicalTrials.gov
From the registry
The goal of this clinical study is to evaluate the safety and efficacy of novel stem cell formulation in patients having Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (d-AMD). The main questions it aims to answer are: * Safety and tolerability of the novel stem cell formulation * Potential efficacy of the novel stem cell formulation Participants will receive a single subretinal injection in their study eye and followed up for safety. This is an India only study and the product is developed indigenously.
Primary outcomes
- Fundus Autofluorescence-
History
Study completion expected
Primary completion
Last registry update
Started
Registered